Woman with silver-streaked dark hair in a taupe sweater looking calmly at the camera
For women newly diagnosed with:
Invasive Ductal Carcinoma3 10
HR+, HER2-, Node -Stage I–IIAny Menopausal StatusNo Prior Treatment
HR = hormone receptor, HER2 = human epidermal growth factor receptor 2

Superior risk stratification for earlier shared decision-making

Superior Risk Stratification+

Eliminates subjectivity and variability of histologic grade

Earlier Shared Decision-Making+
Assesses individual risk
•Low-Risk patients may choose less intervention
•High-Risk patients may require more intervention
Reports chemotherapy benefit
•Low-Risk: No significant benefit
•High-Risk: 12% absolute benefit, 40% risk reduction
Informs when traditional testing yields unclear results
•Borderline results, testing failures, and/or discordant results
Provides accessible testing worldwide in 48 hours
•Digital specimens relieve logistical and financial constraints

Validated for early stage breast cancer

PreciseBreast® was validated in a landmark trial utilizing H&E slides in 1,607 patients from the NSABP B‑20 study providing level 1B evidence for women with hormone receptor positive, node negative, early-stage invasive breast cancer. Median follow-up from randomized ET+CT vs. ET alone arms was 14.2 years. Study objectives validated were the prognostic performance of PreciseBreast® for distant recurrence, the reporting of adjuvant chemotherapy benefit, and the comparison of AI-Grade to histologic grade.

For newly diagnosed women with invasive ductal carcinoma HR+, HER2-, Node -, any menopausal status, no prior treatment.3 10

View Full Poster

How PreciseBreast works

Superior risk stratification for earlier shared decision-making

OncoIntelligence™ analyzes a digitized H&E-stained slide and quantifies the morphologic features & clinical factors that impact the risk of disease recurrence.

Digitized H&E-stained breast tissue slide
1

Digital Pathology

PreciseDx first digitizes the same diagnostic H&E-stained slide a pathologist would use for tumor grading.

Illustration of cells analyzed by AI
2

OncoIntelligence™

OncoIntelligence, our AI-platform, analyzes every cell from the digitized image, objectively quantifying morphologic features that reliably predict 10-year risk of distant recurrence.

Pathologists perform Inference Quality Control to optimize the areas of tumor focus.

Illustration of tumor morphology features
3

Algorithm

The proprietary algorithm delivers the quantitative assessment of the morphologic features as an AI-Grade alone or an AI-Grade that includes 4 clinical factors that measure a patient's 10-year individual risk of distant recurrence.

Data waveform illustration
4

PreciseBreast Report

PreciseBreast AI-Grade is the output of the proprietary algorithm.

PreciseBreast® delivers meaningful cost savings and better patient outcomes to healthcare systems.

PreciseBreast® requires no additional procedures or specialized staff for specimen collection, and it can be accessed from any geographical area in the US or the world.

Precision matters

PreciseBreast® delivers benefits for physicians, patients and payors.

10-year distant recurrence risk

Earlier results lessen anxiety for patients

Lower overall testing and treatment costs

Worldwide access to PreciseBreast®

The latest news

Studies, publications & press releases

Oct 27, 2026

ESMO 26: AI Digital Pathology Models Estimate Chemotherapy Benefit and Risk of Distant Recurrence in Patients From the NSABP B-20 Study

See More

Oct 27, 2026

ESMO 26: AI Digital Pathology Models Estimate Chemotherapy Benefit and Risk of Distant Recurrence in Patients From the NSABP B-20 Study

See More

Dec 4, 2025

PreciseDx Presents New Data for PreciseBreast, an AI Digital Pathology Test to Predict Breast Cancer Recurrence, at the 2025 San Antonio Breast Cancer Symposium

See More

Dec 4, 2025

PreciseDx, the leading innovator behind PreciseBreast, a novel AI digital pathology test, announces the upcoming presentation of three abstracts that further validate the test's ability to assess risk of recurrence in early-stage breast cancer. Ongoing studies aim to demonstrate PreciseBreast's ability to predict treatment benefit.

See More

Aug 20, 2025

External validation of PreciseBreast, a digital prognostic test for predicting breast cancer recurrence, in an early-stage cohort from the Netherlands

See More

Aug 20, 2025

Current clinical guidelines recommend gene expression profiling to guide treatment in early-stage breast cancer. PreciseBreast (PDxBR) is a digital prognostic tool that integrates artificial intelligence (AI)-derived features from hematoxylin and eosin (H&E) slides with clinicopathologic data to predict recurrence risk. This study externally validated PDxBR in an independent cohort and compared its performance to other risk models.

See More

Jun 18, 2025

PreciseDx Continues Path to Commercial Launch: Secures Additional Funding and Announces New Leadership

See More

Jun 18, 2025

Funding now totals over $43 million, strengthened leadership focused on a 2026 commercial launch of the OncoIntelligence™-driven, PreciseBreast™

See More

Let us show you the significance of PreciseBreast®

Contact us today to learn more.

Get in Touch